missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human ALMS1 (aa 3513-3588) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (54%), Rat (54%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-60275 (PA5-60275. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
THRAP3 is a 955 amino acid novel nuclear receptor and a member of the Thyroid hormone receptor associated proteins with a LISH domain and no obvious known sequence motifs. THRAP3 is a 150 kDa subunit of the large multiprotein complex TRAP and is important in the maintenance of the fundamental structure of the fibrillar center and dense fibrillar component in the nucleolus. It is also known to play an important role in transcriptional coactivation. It is known to interact with DKC1, nop5/nap65 and fibrillarin. From the Northern blot analysis of several human tissues it was found that TRAP150 is ubiquitously expressed.
Specifications
Specifications
| Accession Number | Q8TCU4 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 7840 |
| Name | Human ALMS1 (aa 3513-3588) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | Alms1; ALMS1, centrosome and basal body associated protein; ALSS; Alstrom syndrome 1; Alstrom syndrome 1 homolog; Alstrom syndrome protein 1; DKFZp686A118; DKFZp686D1828; KIAA0328 |
| Common Name | ALMS1 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction